These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20845250)

  • 21. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 23. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review.
    Zechmeister-Koss I; Huic M
    Br J Ophthalmol; 2012 Feb; 96(2):167-78. PubMed ID: 22133986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-VEGF therapy to treat diabetic macular edema].
    Takamura Y
    Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
    [No Abstract]   [Full Text] [Related]  

  • 27. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
    Ollendorf DA; Colby JA; Pearson SD
    Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
    Naser H; Koss MJ; Singh P; Koch F
    Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
    Uludag G; Hassan M; Matsumiya W; Pham BH; Chea S; Trong Tuong Than N; Doan HL; Akhavanrezayat A; Halim MS; Do DV; Nguyen QD
    Expert Opin Biol Ther; 2022 Oct; 22(10):1275-1291. PubMed ID: 35818801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
    Sonoda Y; Arimura N; Shimura M; Sakamoto T
    Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of diabetic macular oedema with the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic in vitro studies].
    Lang GE; Lang GK; Deissler HL
    Klin Monbl Augenheilkd; 2014 May; 231(5):527-34. PubMed ID: 24799173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.
    Prescrire Int; 2015 Sep; 24(163):207. PubMed ID: 26417628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results of an expert survey on VEGF inhibitors in ophthalmology].
    Kühn T
    Klin Monbl Augenheilkd; 2011 Jul; 228(7):607-12. PubMed ID: 21472638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retinal artery occlusion following intravitreal anti-VEGF therapy.
    von Hanno T; Kinge B; Fossen K
    Acta Ophthalmol; 2010 Mar; 88(2):263-6. PubMed ID: 19416108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
    Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of anti-VEGF therapy in proliferative diabetic retinopathy.
    Jardeleza MS; Miller JW
    Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.